ISSN: 2578-4641
Authors: Yastrebova ES, Prostov MY, Komarova LE, Gurevich LE and Gorbunova VA*
The Incidence of NETs has increased 6,4 - fold over the last 40 years. This growth is noted by statistics from most countries of the world. This is due to both improved diagnosis and the actual increase in this type of disease. Russia according to 2017 data had the largest population and largest number of registered NET patients among the incomplete list of European countries as well as the second place regarding the prevalence of NETs. From 2017 to 2019 the number of NET patients included in the National Cancer Registry of the Russian Federation has increased from 21 668 NET patients (prevalence - 14.75 per 100,000 population) to 25,782. In 2019, the prevalence of NETs was 17.54 per 100,000 population. If over a 10- year period (2010 -2019) the number of patients with malignant tumors followed-up in oncology dispensaries has increased by 40.6%, the number of patients with confirmed diagnosis of neuroendocrine tumors increased by 83.9%. The number of newly identified cases of NETs increased much more intensively than number of all malignant tumor during the same period also: in 2019, the number of newly identified cases was 1.8-fold larger than it had been in 2010 - respectively 7,623 and 4,198 cases. The increase in the incidence of NETs has been 3.5-fold larger than the increase in the total number of cases of malignant tumors. The article presents the results of the analysis of the data of the state cancer registry and separately shows the results of the register of the medical society for the treatment of neuroendocrine tumors (MOLNEO).
Keywords: Neuroendocrine Tumors; Epidemiology; Incidence; Prevalence; Population; Register
